AMGN supply chain intelligence for Amgen Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
Amgen Inc. (AMGN) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
Amgen's supply chain spans biologics manufacturing, drug development, distribution, licensing, and healthcare customer relationships. ChainSifter tracks verified public-company relationships for Amgen.
Use this AMGN supply chain page to inspect supplier, customer, and related biotech or pharmaceutical chain data.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| HBIO | Harvard Bioscience, Inc. | 92% | Reciprocal relationship from HBIO graph: Reciprocal relationship from AMGN graph: Reciprocal relationship from HBIO graph: Reciprocal relationship from AMGN graph: Reciprocal relationship from HBIO g… |
| PODD | Insulet Corporation | 92% | Reciprocal relationship from PODD graph: Reciprocal relationship from AMGN graph: Reciprocal relationship from PODD graph: Reciprocal relationship from AMGN graph: Reciprocal relationship from PODD g… |
| TCRX | TScan Therapeutics, Inc. | 92% | Reciprocal relationship from TCRX graph: The Company concluded that Amgen meets the definition of a customer, as the Company is delivering research and development activities and a license of intelle… |
| CTMX | CytomX Therapeutics, Inc. | 90% | Reciprocal relationship from CTMX graph: Reciprocal relationship from AMGN graph: Reciprocal relationship from CTMX graph: In September 2017, we entered into a Collaboration and License Agreement (th… |
| ONC | BeOne Medicines AG | 90% | Reciprocal relationship from ONC graph: Reciprocal relationship from AMGN graph: Reciprocal relationship from ONC graph: Reciprocal relationship from AMGN graph: Reciprocal relationship from ONC grap… |
| ARWR | Arrowhead Pharmaceuticals, Inc. | 80% | Reciprocal relationship from ARWR graph: Reciprocal relationship from AMGN graph: Reciprocal relationship from ARWR graph: The Company remains eligible to receive any milestone payments potentially p… |
| ALVO | Alvotech | 62% | Reciprocal relationship from ALVO graph: Reciprocal relationship from AMGN graph: Reciprocal relationship from ALVO graph: Reciprocal relationship from AMGN graph: Reciprocal relationship from ALVO g… |
| BIOA | BioAge Labs, Inc. | 62% | Reciprocal relationship from BIOA graph: Reciprocal relationship from AMGN graph: Reciprocal relationship from BIOA graph: Reciprocal relationship from AMGN graph: Reciprocal relationship from BIOA g… |
| IMNM | Immunome, Inc. | 62% | Reciprocal relationship from IMNM graph: security incident or other interruption that has, and could in the future, result in unauthorized, unlawful, or accidental acquisition, modification, destruct… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| USGOV-DEPARTMENT-OF-HEALTH-AND-HUMAN-SERVICES | USGOV-DEPARTMENT-OF-HEALTH-AND-HUMAN-SERVICES | 95% | USAspending awards from Department of Health and Human Services: $26,408,674 across 1 awards. 75A50119C00061 THIS CONTRACT IS TO ADVANCE THE DEVELOPMENT OF ROMIPLOSTIM FOR TREATMENT OF HEMATOPOIETIC … |
| CTMX | CytomX Therapeutics, Inc. | 90% | Reciprocal relationship from CTMX graph: In September 2017, we entered into a Collaboration and License Agreement (the "Amgen Agreement") with Amgen. |
| CUZ | Cousins Properties Incorporated | 90% | Reciprocal relationship from CUZ graph: 14 Amgen 1 1 163,169 6,833 0.8% 3.8 |
| NAUT | Nautilus Biotechnology, Inc. | 90% | Reciprocal relationship from NAUT graph: In October 2021, we entered into a research collaboration agreement with Amgen in which the Nautilus platform may be used across a number of projects |
| NMRA | Neumora Therapeutics, Inc. | 90% | Reciprocal relationship from NMRA graph: Additionally, Amgen purchased 12.7 million shares of our Series A-2 Preferred Stock at a purchase price of $7.85 per share, for total consideration of $100.0 … |
| UNH | UnitedHealth Group Incorporated | 85% | Reciprocal relationship from UNH graph: Reciprocal relationship from AMGN graph: ded December 31, 2025, Part I, Item 1A. Risk Factors —Concentration of sales at certain of our wholesaler distributors… |
| UNITED-HEALTH-GROUP | UNITED-HEALTH-GROUP | 85% | ded December 31, 2025, Part I, Item 1A. Risk Factors —Concentration of sales at certain of our wholesaler distributors, and consolidation of private payers, such as insurers, and PBMs has negatively … |
| ONC | BeOne Medicines AG | 80% | Reciprocal relationship from ONC graph: Reciprocal relationship from AMGN graph: Reciprocal relationship from ONC graph: Reciprocal relationship from AMGN graph: Reciprocal relationship from ONC grap… |
| BEONE-MEDICINES-LTD | BEONE-MEDICINES-LTD | 62% | ion, respectively. (2) During the three months ended March 31, 2026 and 2025, manufacturing cost of sales included amortization of step-up to fair value of inventory acquired in business combinations… |
| SOLARWINDS-CORPORATION | SOLARWINDS-CORPORATION | 62% | e our business, including developing, gaining regulatory approval for, manufacturing, selling and/or distributing our products. For example, in 2017, a pharmaceutical company experienced a cyberattac… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| AMGN-DEBT | Debt stack $53.9B | 90% | Market cache reports total debt of $53.9B. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| AMGN-OWNER-CAPITAL-WORLD-INVESTORS | Capital World Investors | 95% | 13F/ownership overlay lists Capital World Investors; shares held 29,288,343; value $10.30T; as of 2026-03-31. |
| AMGN-OWNER-GOLDMAN-SACHS-GROUP-INC | GOLDMAN SACHS GROUP INC | 95% | 13F/ownership overlay lists GOLDMAN SACHS GROUP INC; shares held 9,017,647; value $3.06T; as of 2026-03-31. |
| AMGN-OWNER-VANGUARD-PORTFOLIO-MANAGEMENT-LLC | VANGUARD PORTFOLIO MANAGEMENT LLC | 95% | 13F/ownership overlay lists VANGUARD PORTFOLIO MANAGEMENT LLC; shares held 14,621,148; value $5.14T; as of 2026-03-31. |
| AMGN-OWNER-GEODE-CAPITAL-MANAGEMENT-LLC | GEODE CAPITAL MANAGEMENT, LLC | 95% | 13F/ownership overlay lists GEODE CAPITAL MANAGEMENT, LLC; shares held 15,430,524; value $5.41T; as of 2026-03-31. |
| AMGN-OWNER-STATE-STREET-CORP | STATE STREET CORP | 95% | 13F/ownership overlay lists STATE STREET CORP; shares held 30,548,488; value $10.75T; as of 2026-03-31. |
| AMGN-OWNER-CHARLES-SCHWAB-INVESTMENT-MANAGEMENT-INC | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 95% | 13F/ownership overlay lists CHARLES SCHWAB INVESTMENT MANAGEMENT INC; shares held 12,773,386; value $4.49T; as of 2026-03-31. |
| AMGN-OWNER-MORGAN-STANLEY | MORGAN STANLEY | 95% | 13F/ownership overlay lists MORGAN STANLEY; shares held 47,491,111; value $15.22T; as of 2026-03-31. |
| AMGN-OWNER-BLACKROCK-INC | BlackRock, Inc. | 95% | 13F/ownership overlay lists BlackRock, Inc.; shares held 47,100,472; value $16.57T; as of 2026-03-31. |
| AMGN-OWNER-BARCLAYS-PLC | BARCLAYS PLC | 95% | 13F/ownership overlay lists BARCLAYS PLC; shares held 32,598,592; value $9.46T; as of 2026-03-31. |
| AMGN-OWNER-VANGUARD-CAPITAL-MANAGEMENT-LLC | VANGUARD CAPITAL MANAGEMENT LLC | 95% | 13F/ownership overlay lists VANGUARD CAPITAL MANAGEMENT LLC; shares held 70,028,464; ownership 12.95%; value $24.64T; as of 2026-03-31. |
| AMGN | Amgen Inc. | 82% | Grygiel Nancy A. | SVP & CCO | buy | 787 shares |
| AMGN | Amgen Inc. | 82% | Khosla Rachna | SVP, Business Development | option_exercise | 707 shares |
| AMGN | Amgen Inc. | 82% | Miller Derek | SVP, Human Resources | option_exercise | 1616 shares |
| AMGN | Amgen Inc. | 82% | David M. Reese | EVP & Chief Technology Officer | option_exercise | 6022 shares |
| AMGN | Amgen Inc. | 82% | Santos Esteban | EVP, Operations | buy | 5621 shares |
| AMGN | Amgen Inc. | 82% | Bradway Robert A | Chairman, CEO and President | option_exercise | 119782 shares |
| AMGN | Amgen Inc. | 82% | Gordon Murdo | EVP, Global Commercial Ops | option_exercise | 13403 shares |
| AMGN | Amgen Inc. | 82% | Bradway Robert A | Chairman, CEO and President | buy | 90000 shares |
| AMGN | Amgen Inc. | 82% | David M. Reese | EVP & Chief Technology Officer | option_exercise | 12063 shares |
| AMGN | Amgen Inc. | 82% | Derek Miller | SVP, Human Resources | option_exercise | 3484 shares |
| AMGN | Amgen Inc. | 82% | Khosla Rachna | SVP, Business Development | option_exercise | 1876 shares |
| AMGN | Amgen Inc. | 82% | Grygiel Nancy A. | SVP & CCO | buy | 9249 shares |
| AMGN | Amgen Inc. | 82% | Griffith Peter H. | EVP & CFO | option_exercise | 12063 shares |
| AMGN | Amgen Inc. | 82% | Graham Jonathan P | EVP & Gen. Counsel & Sec. | option_exercise | 10723 shares |
| AMGN | Amgen Inc. | 82% | Busch Matthew C. | VP, Finance & CAO | option_exercise | 938 shares |
| AMGN | Amgen Inc. | 82% | Bradway Robert A | Chairman, CEO and President | buy | 90000 shares |
| AMGN | Amgen Inc. | 82% | Gordon Murdo | EVP, Global Commercial Ops | option_exercise | 13403 shares |
| AMGN | Amgen Inc. | 82% | Graham Jonathan P | EVP & Gen. Counsel & Sec. | option_exercise | 10723 shares |
| AMGN | Amgen Inc. | 82% | Griffith Peter H. | EVP & CFO | option_exercise | 12063 shares |
| AMGN | Amgen Inc. | 82% | Grygiel Nancy A. | SVP & CCO | buy | 9249 shares |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| PODD | Insulet Corporation | 100.00 | 1 | ['supplier'] |
| CUZ | Cousins Properties Incorporated | 100.00 | 1 | ['customer'] |
| NAUT | Nautilus Biotechnology, Inc. | 100.00 | 1 | ['customer'] |
| ONC | BeOne Medicines AG | 100.00 | 1 | ['customer', 'supplier'] |
| ABBVIE | ABBVIE | 100.00 | 2 | |
| IMNM | Immunome, Inc. | 100.00 | 1 | ['supplier'] |
| HBIO | Harvard Bioscience, Inc. | 100.00 | 1 | ['supplier'] |
| TCRX | TScan Therapeutics, Inc. | 100.00 | 1 | ['supplier'] |
| NMRA | Neumora Therapeutics, Inc. | 100.00 | 1 | ['customer'] |
| CTMX | CytomX Therapeutics, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| UNH | UnitedHealth Group Incorporated | 100.00 | 1 | ['customer'] |
| AMGEN | AMGEN | 100.00 | 2 | |
| ALVO | Alvotech | 100.00 | 1 | ['supplier'] |
| ARWR | Arrowhead Pharmaceuticals, Inc. | 100.00 | 1 | ['supplier'] |
| BIOA | BioAge Labs, Inc. | 100.00 | 1 | ['supplier'] |
| SEM | Select Medical Holdings Corporation | 50.00 | 2 | |
| ORANY | ORANGE | 50.00 | 2 | |
| DYN | Dyne Therapeutics, Inc. | 50.00 | 2 | |
| ADP | Automatic Data Processing, Inc. | 50.00 | 2 | |
| REGN | Regeneron Pharmaceuticals, Inc. | 50.00 | 2 |